Nilsson C, Mäkitalo B, Berglund P, Bex F, Liljeström P, Sutter G, Erfle V, ten Haaft P, Heeney J, Biberfeld G, Thorstensson R
Swedish Institute for Infectious Disease Control, SE-171 82, Solna, Sweden.
Vaccine. 2001 May 14;19(25-26):3526-36. doi: 10.1016/s0264-410x(01)00034-2.
The immunogenicity of two vector-based vaccines, either given alone or in a prime-boost regimen, was investigated. Cynomolgus macaques were immunised with modified vaccinia virus Ankara (MVA) expressing simian immunodeficiency virus (SIV)macJ5 env, gag-pol, nef, rev, and tat genes (MVA-SIVmac) or primed with a Semliki forest virus (SFV) vaccine expressing the same genes (SFV-SIVmac) and boosted with MVA-SIVmac. Generally, antibody responses, T-cell proliferative responses and cytotoxic T-cell responses remained low or undetectable in vaccinees receiving MVA-SIVmac or SFV-SIVmac alone. In contrast, monkeys who first received SFV-SIVmac twice and then were boosted with MVA-SIVmac showed increased antibody responses as well as high T-cell proliferative responses. Three of these vaccinees had cytotoxic T-lymphocytes directed against three or four of the gene products. No evidence of protection was seen against an intrarectal heterologous SIVsm challenge given 3 months after the last immunisation. The study demonstrates a prime-boost strategy that efficiently induces both humoral and cellular immune responses.
研究了两种基于载体的疫苗单独接种或采用初免-加强免疫方案接种时的免疫原性。用表达猴免疫缺陷病毒(SIV)macJ5 env、gag-pol、nef、rev和tat基因的改良安卡拉痘苗病毒(MVA)(MVA-SIVmac)免疫食蟹猴,或先用表达相同基因的塞姆利基森林病毒(SFV)疫苗(SFV-SIVmac)进行初免,再用MVA-SIVmac进行加强免疫。一般来说,单独接种MVA-SIVmac或SFV-SIVmac的疫苗接种者的抗体反应、T细胞增殖反应和细胞毒性T细胞反应仍然较低或无法检测到。相比之下,先接受两次SFV-SIVmac初免,然后用MVA-SIVmac进行加强免疫的猴子,其抗体反应增强,T细胞增殖反应也较高。其中三名疫苗接种者产生了针对三种或四种基因产物的细胞毒性T淋巴细胞。在最后一次免疫后3个月进行直肠内异源SIVsm攻击时,未观察到保护作用的证据。该研究证明了一种能有效诱导体液免疫和细胞免疫反应的初免-加强免疫策略。